<DOC>
	<DOC>NCT01756703</DOC>
	<brief_summary>The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria</brief_summary>
	<brief_title>A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Subjects with Type II diabetic nephropathy, who have been treated with angiotensin converting enzymeinhibitor (ACEI) or angiotensin II receptor blocker (ARB) Glycosylated haemoglobin (HbA1c) ≤10.5% An estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m^2 Subject with albuminuria History of Type I diabetes, pancreas or βcell transplantation, or diabetes secondary to pancreatitis or pancreatectomy Serum potassium level &lt;3.5 or &gt;5.0 mmol/L Subjects who had acute kidney injury (AKI) within 3 months prior to baseline or have undergone renal dialysis at any time prior to randomisation Subjects with a history of renal transplant Subjects with clinically significant hypotension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>